Reine Lifescience

What Reine Lifescience does

Reine Lifescience is a privately held Indian active pharmaceutical ingredient (API) manufacturer headquartered in Ankleshwar, Gujarat, that also operates as a contract development and manufacturing organization (CDMO) for global pharmaceutical clients. Founded in 1993 as Reine Chemicals Pvt. Ltd. and rebranded in 2014-2015 to reflect its pivot into regulated pharmaceutical APIs, the company runs cGMP-compliant manufacturing facilities spanning more than 20,000 square meters with 200+ KL of reactor capacity and approximately 2,000 MT/year of API production output. Its commercial portfolio covers roughly 27-29 APIs across therapeutic categories such as cardiovascular, anti-hypertensive, anti-diabetic, anti-epilepsy, anticoagulant, neuropathic pain, anti-allergic, anti-asthmatic, and iron chelation, manufactured to IP, BP, EP, and USP pharmacopeial standards, with five additional APIs in development.

The company holds a layered regulatory stack — WHO-GMP, CEP/EDQM, MFDS Korea, ANVISA (post-2026 inspection), and ISO 9001/14001/45001 — and exports to 45+ countries across South Asia, Asia Pacific, Europe, and global markets. Its technical capabilities rest on advanced organic synthesis (cyclization, condensations, hydrogenation, Friedel-Crafts, coupling reactions), impurity profiling, 200+ validated analytical methods, and an integrated R&D-to-commercial scale-up pipeline anchored by a three-pillar basic/applied/experimental research framework. Quality assurance is supported by HPLC, GC, UV, FTIR, and stability-chamber instrumentation.

Reine Lifescience operates a direct B2B enterprise sales model with quote-based pricing, regional sales teams split between Pan India and International, and lead generation conducted primarily through CPHI pharmaceutical trade exhibitions in Thailand, Korea, Frankfurt, India, and China. The company is founder/management-controlled under Managing Director Kalpesh Kothiya and directors Amish Shah and Devang Shah, with no disclosed institutional investor or parent company and no publicly reported revenue or funding data.

Name

Reine Lifescience

Legal name

Reine Lifescience

Website

https://reinelifescience.com

Company type

Private

Founded year

1993

Operating status

Operating

Ownership category

akta.pro rank

Product category

Active Pharmaceutical Ingredients (APIs)

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)

SIC

Medicinal Chemicals & Botanical Products (2833), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Small-Molecule API Process Development & Route Scouting (HLAGAHAA)

akta.pro secondary industries

Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), Impurity / Reference Standard Synthesis & Characterization (HLAGAHAG), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Quality Engineering & Risk Management (ICH Q9/Q10, validation, change control) (HLAGAKAL)

Keywords

• Active pharmaceutical ingredients
• API manufacturing
• Contract development manufacturing
• Pharmaceutical intermediates
• CDMO services

Headquarters

HQ city

Ankleshwar

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. API Manufacturing and Sales: Manufacturing and selling Active Pharmaceutical Ingredients (APIs) to pharmaceutical companies worldwide. Revenue generated through direct B2B sales of pharmaceutical-grade APIs meeting global regulatory standards including WHO-GMP, CEP, and pharmacopeial requirements (IP, BP, EP, USP).

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Reine Lifescience manufactures and sells Active Pharmaceutical Ingredients (APIs) and advanced pharmaceutical intermediates from its cGMP-compliant facilities in Ankleshwar, Gujarat, India. The company offers a portfolio of 27 commercialized APIs and 5 under development spanning therapeutic categories including cardiovascular, anti-hypertensive, anti-diabetic, anticoagulant, and anti-epilepsy medications. It also provides integrated CDMO (Contract Development & Manufacturing Organization) services, R&D services (organic synthesis, impurity profiling, analytical method validation), and quality assurance/control to pharmaceutical companies in regulated markets worldwide.

Product overview

Reine Lifescience offers a unified portfolio centered on Active Pharmaceutical Ingredients (APIs) manufacturing, complemented by integrated CDMO services. The core offering consists of 27+ commercialized APIs and 5 products under development, spanning therapeutic categories including cardiovascular, anti-hypertensive, anti-diabetic, anticoagulant, and anti-epilepsy medications. These are supported by research and development services (organic synthesis, impurity profiling, analytical method validation), quality assurance and control systems, and cGMP-compliant manufacturing capabilities. The company operates as both an API manufacturer and a full-service CDMO partner, providing end-to-end solutions from molecule development through commercial-scale production.

Differentiator

Problem solved

Functional benefit

Products and services

• Active Pharmaceutical Ingredients (APIs) High-purity pharmaceutical APIs manufactured in WHO-GMP and CEP certified facilities, serving regulated markets worldwide to IP, BP, EP, and USP pharmacopeial standards. Portfolio includes products such as Amiodarone HCL, Apixaban, Atorvastatin Calcium, Metoprolol Succinate, Pregabalin, Rosuvastatin Calcium, and Sitagliptin Phosphate Monohydrate, among others.
• CDMO Services End-to-end Contract Development & Manufacturing Organization services providing process development, analytical development, manufacturing, and regulatory support from early development through commercial scale production. Targeted at pharmaceutical companies seeking regulatory-compliant contract manufacturing partners.
• Research & Development Innovation-driven research and development services focused on developing cost-effective and scalable processes for pharmaceutical intermediates and APIs, including organic synthesis, impurity profiling, and analytical method validation aligned with ICH guidelines.
• Quality Assurance & Quality Control Integrated QA/QC systems ensuring every API consistently meets stringent global cGMP standards, with advanced analytical laboratories (HPLC, GC, UV spectrophotometers, FTIR, stability chambers) and comprehensive documentation control.
• Manufacturing cGMP-compliant manufacturing facilities with 200+ KL reactor capacity and 2000+ MT/year production capability, featuring dedicated cleanroom facilities and integrated R&D, QC, and QA laboratories located in Ankleshwar, Gujarat, India.

Quantifiable outcome

• 50+ API products manufactured with regulatory compliance
• +3 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Granules India: Indian API and finished-formulation manufacturer with focus on high-volume small-molecule categories. Comparable to Reine on API manufacturing scale, regulatory certification profile, and customer segment.
• Neuland Laboratories: India-based small-molecule API manufacturer and CDMO serving global pharma with WHO-GMP, USFDA, and EDQM approvals. Closely comparable to Reine in scale, therapeutic category focus, and CDMO+R&D service profile.
• Jubilant Ingrevia: Indian specialty chemicals and CDMO business of Jubilant with API and intermediates manufacturing for global pharma. Comparable to Reine in small-molecule API, custom synthesis, and life science chemistry services.
• Piramal Pharma Solutions: Global CDMO business of Piramal Pharma providing API manufacturing and drug development services with multiple regulatory inspections. Operates in the same end-to-end small-molecule CDMO space as Reine.
• Suven Life Sciences (now Suven Pharmaceuticals): Indian pharma company focused on API manufacturing, CDMO services, and specialty intermediates with regulated-market approvals. Direct peer given shared NCE API/CDMO and contract manufacturing profile.
• Sai Life Sciences: Indian CDMO offering contract research, process development, and small-molecule API manufacturing with regulatory compliance. Directly comparable to Reine's CDMO and R&D service layer targeting innovator and generic pharma.
• Divis Laboratories: Leading Indian API manufacturer and CDMO with deep small-molecule generics and custom synthesis capabilities across regulated markets. Directly comparable to Reine's API manufacturing and CDMO service offering at significantly larger scale.
• Laurus Labs: Indian API and CDMO player with a diversified small-molecule portfolio spanning anti-retrovirals, cardiovascular, and other therapeutic categories. Comparable to Reine in API manufacturing focus, regulatory certifications, and CDMO services.

Broad incumbents

• Sequent Scientific: Indian animal health and API manufacturer with operations in regulated markets. A broader incumbent peer given its API manufacturing infrastructure and global regulatory footprint.
• Aurobindo Pharma: Large Indian pharmaceutical company with vertically integrated API and finished-dosage operations across cardiovascular, anti-diabetic, and other categories. Reine's overlap on the API side makes it a relevant broader incumbent reference.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/reine-lifescience

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Reine Lifescience